| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 1.41M | 8.35M | 15M | 78M | 383M | 112M | 117M | 258M |
| Revenue Growth % | - | - | 4.91% | 0.8% | 4.2% | 3.91% | -0.71% | 0.04% | 1.21% |
| Cost of Goods Sold | 1.31M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -1.31M | 1.41M | 8.35M | 15M | 78M | 383M | 112M | 117M | 258M |
| Gross Margin % | - | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | 2.08% | 4.91% | 0.8% | 4.2% | 3.91% | -0.71% | 0.04% | 1.21% |
| Operating Expenses | 18.18M | 54.85M | 63.21M | 103.71M | 202M | 329M | 392M | 457M | 588M |
| OpEx % of Revenue | - | 38.82% | 7.57% | 6.91% | 2.59% | 0.86% | 3.5% | 3.91% | 2.28% |
| Selling, General & Admin | 3.94M | 7.64M | 13.57M | 25.23M | 43M | 72M | 104M | 117M | 120M |
| SG&A % of Revenue | - | 5.4% | 1.62% | 1.68% | 0.55% | 0.19% | 0.93% | 1% | 0.47% |
| Research & Development | 14.25M | 47.22M | 49.65M | 78.48M | 159M | 257M | 288M | 340M | 448M |
| R&D % of Revenue | - | 33.42% | 5.94% | 5.23% | 2.04% | 0.67% | 2.57% | 2.91% | 1.74% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20M |
| Operating Income | -18.18M | -53.44M | -54.86M | -88.71M | -124M | 54M | -280M | -340M | -330M |
| Operating Margin % | - | -37.82% | -6.57% | -5.91% | -1.59% | 0.14% | -2.5% | -2.91% | -1.28% |
| Operating Income Growth % | - | -1.94% | -0.03% | -0.62% | -0.4% | 1.44% | -6.19% | -0.21% | 0.03% |
| EBITDA | -16.87M | -50.83M | -51.2M | -85.13M | -121M | 58M | -274M | -332M | -320M |
| EBITDA Margin % | - | -35.97% | -6.13% | -5.68% | -1.55% | 0.15% | -2.45% | -2.84% | -1.24% |
| EBITDA Growth % | - | -2.01% | -0.01% | -0.66% | -0.42% | 1.48% | -5.72% | -0.21% | 0.04% |
| D&A (Non-Cash Add-back) | 1.31M | 2.61M | 3.66M | 3.58M | 3M | 4M | 6M | 8M | 10M |
| EBIT | -18.18M | -53.44M | -54.86M | -84.71M | -123M | 55M | -264M | -299M | -279M |
| Net Interest Income | 0 | 775K | 4.92M | 5.2M | 1M | 1M | 14M | 39M | 48M |
| Interest Income | 212K | 775K | 4.92M | 5.2M | 1M | 1M | 16M | 41M | 52M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 2M | 2M | 4M |
| Other Income/Expense | 212K | 359K | 5.26M | 4M | 1M | 1M | 14M | 39M | 47M |
| Pretax Income | -17.97M | -53.08M | -49.59M | -84.71M | -123M | 55M | -266M | -301M | -283M |
| Pretax Margin % | - | -37.57% | -5.94% | -5.65% | -1.58% | 0.14% | -2.38% | -2.57% | -1.1% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 2M | 1M | 6M | 1M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 0.96% | 1% | 1.02% | 1% |
| Net Income | -17.97M | -53.08M | -49.59M | -84.71M | -123M | 53M | -267M | -307M | -283M |
| Net Margin % | - | -37.57% | -5.94% | -5.65% | -1.58% | 0.14% | -2.38% | -2.62% | -1.1% |
| Net Income Growth % | - | -1.95% | 0.07% | -0.71% | -0.45% | 1.43% | -6.04% | -0.15% | 0.08% |
| Net Income (Continuing) | -17.97M | -53.08M | -49.59M | -84.71M | -123M | 53M | -267M | -307M | -284M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.73 | -2.16 | -1.43 | -1.73 | -2.13 | 0.71 | -3.71 | -4.15 | -3.14 |
| EPS Growth % | - | -1.96% | 0.34% | -0.21% | -0.23% | 1.33% | -6.23% | -0.12% | 0.24% |
| EPS (Basic) | -0.73 | -2.16 | -1.43 | -1.73 | -2.13 | 0.76 | -3.71 | -4.15 | -3.14 |
| Diluted Shares Outstanding | 24.55M | 24.55M | 34.62M | 43.83M | 54.79M | 73.97M | 72M | 74M | 90.1M |
| Basic Shares Outstanding | 24.55M | 24.55M | 34.62M | 43.83M | 54.79M | 69.35M | 72M | 74M | 90.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 99.69M | 176.87M | 258.95M | 192.71M | 735.82M | 1.26B | 1.07B | 831M | 1.02B |
| Cash & Short-Term Investments | 98.9M | 175.7M | 256.54M | 188.27M | 728.65M | 499.31M | 1.01B | 759M | 978M |
| Cash Only | 65.16M | 98.43M | 71.06M | 57.94M | 173.41M | 147.91M | 206M | 127M | 150M |
| Short-Term Investments | 33.74M | 77.28M | 185.48M | 130.33M | 555.23M | 351.39M | 803M | 632M | 828M |
| Accounts Receivable | 405K | 25K | 83K | 132K | 1.7M | 746.82M | 43M | 42M | 25M |
| Days Sales Outstanding | - | 6.46 | 3.63 | 3.21 | 7.95 | 711.72 | 140.13 | 131.03 | 35.37 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 251K | 4.47M | 14.72M | 14M | 30M | 13M |
| Total Non-Current Assets | 10.01M | 13.62M | 15.98M | 10.4M | 36.48M | 330.15M | 279M | 264M | 134M |
| Property, Plant & Equipment | 8.61M | 11.23M | 11.11M | 9.33M | 23.59M | 137.42M | 135M | 51M | 47M |
| Fixed Asset Turnover | - | 0.13x | 0.75x | 1.61x | 3.31x | 2.79x | 0.83x | 2.29x | 5.49x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1M | 682K | 4.38M | 0 | 6.64M | 185M | 134M | 107M | 14M |
| Other Non-Current Assets | 403K | 1.71M | 487K | 1.07M | 6.25M | 7.73M | 10M | 106M | 73M |
| Total Assets | 109.7M | 190.49M | 274.93M | 203.11M | 772.29M | 1.59B | 1.34B | 1.09B | 1.15B |
| Asset Turnover | - | 0.01x | 0.03x | 0.07x | 0.10x | 0.24x | 0.08x | 0.11x | 0.22x |
| Asset Growth % | - | 0.74% | 0.44% | -0.26% | 2.8% | 1.06% | -0.16% | -0.19% | 0.05% |
| Total Current Liabilities | 5.55M | 12.73M | 16.93M | 22.71M | 121.67M | 166.08M | 193M | 184M | 226M |
| Accounts Payable | 3.87M | 3.82M | 3.1M | 4.7M | 15.68M | 10.26M | 20M | 17M | 18M |
| Days Payables Outstanding | 1.07K | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 2.87M | 5.1M | 3M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 682K | 769K | 1.56M | 6.43M | 19.92M | 30.26M | 48M | 39M | 14M |
| Current Ratio | 17.98x | 13.90x | 15.29x | 8.49x | 6.05x | 7.60x | 5.52x | 4.52x | 4.50x |
| Quick Ratio | 17.98x | 13.90x | 15.29x | 8.49x | 6.05x | 7.60x | 5.52x | 4.52x | 4.50x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 4.7M | 23.89M | 23.05M | 16.56M | 148.32M | 584.36M | 495M | 449M | 439M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 48M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 15.24M | 116.89M | 117M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4.7M | 5.3M | 6.06M | 4.54M | 10.25M | 5.26M | 23M | 142M | 157M |
| Total Liabilities | 10.24M | 36.62M | 39.98M | 39.27M | 269.99M | 750.45M | 688M | 633M | 665M |
| Total Debt | 0 | 0 | 0 | 0 | 18.11M | 121.99M | 120M | 11M | 60M |
| Net Debt | -65.16M | -98.43M | -71.06M | -57.94M | -155.31M | -25.93M | -86M | -116M | -90M |
| Debt / Equity | - | - | - | - | 0.04x | 0.14x | 0.18x | 0.02x | 0.12x |
| Debt / EBITDA | - | - | - | - | - | 2.10x | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | -0.45x | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -140.00x | -170.00x | -82.50x |
| Total Equity | 99.46M | 153.87M | 234.94M | 163.84M | 502.3M | 841.45M | 657M | 462M | 485M |
| Equity Growth % | - | 0.55% | 0.53% | -0.3% | 2.07% | 0.68% | -0.22% | -0.3% | 0.05% |
| Book Value per Share | 4.05 | 6.27 | 6.79 | 3.74 | 9.17 | 11.38 | 9.13 | 6.24 | 5.38 |
| Total Shareholders' Equity | 99.46M | 153.87M | 234.94M | 163.84M | 502.3M | 841.45M | 657M | 462M | 485M |
| Common Stock | 1K | 3K | 4K | 4K | 6K | 7K | 1.21B | 1.31B | 1.62B |
| Retained Earnings | -20.15M | -73.23M | -122.83M | -205.33M | -328.18M | -275.35M | -542M | -849M | -1.13B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -26K | -42K | -107K | 64K | 44K | -1.26M | -7M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.94M | -25.06M | -43M | -73.46M | 111.17M | -256.17M | 438M | -306M | -170M |
| Operating CF Margin % | - | -17.73% | -5.15% | -4.9% | 1.43% | -0.67% | 3.91% | -2.62% | -0.66% |
| Operating CF Growth % | - | -0.94% | -0.72% | -0.71% | 2.51% | -3.3% | 2.71% | -1.7% | 0.44% |
| Net Income | -17.97M | -53.08M | -49.59M | -84.71M | -122.86M | 52.83M | -267M | -307M | -283M |
| Depreciation & Amortization | 1.31M | 2.61M | 3.66M | 3.58M | 4.19M | 3.84M | 14M | 8M | 10M |
| Stock-Based Compensation | 90K | 495K | 3.87M | 8.98M | 22M | 55M | 0 | 73M | 76M |
| Deferred Taxes | -90K | 416K | -2.1M | 0 | 0 | 4.77M | 0 | 0 | 0 |
| Other Non-Cash Items | 90K | -98K | -177K | -1.44M | -46K | 3.47M | 68M | -9M | 5M |
| Working Capital Changes | 3.62M | 24.6M | 1.33M | 125K | 208.06M | -375.62M | 623M | -71M | 22M |
| Change in Receivables | 0 | 380K | -58K | -49K | -917K | -17.05M | 704M | 15M | 28M |
| Change in Inventory | 0 | 0 | 0 | 0 | 21.32M | 14.09M | 0 | 0 | 0 |
| Change in Payables | 3.57M | -267K | -69K | 1.73M | 9.27M | -4.77M | 8M | -1M | 3M |
| Cash from Investing | -38.86M | -49.07M | -113.44M | 59.21M | -434.37M | -3.87M | -413M | 194M | -84M |
| Capital Expenditures | -4.1M | -5.51M | -3.74M | -1.93M | -3.06M | -26.08M | -6M | -24M | -6M |
| CapEx % of Revenue | - | 3.9% | 0.45% | 0.13% | 0.04% | 0.07% | 0.05% | 0.21% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -1M | -43.56M | -109.7M | 0 | -431M | 22M | -3M | 0 | 0 |
| Cash from Financing | 70.1M | 107.4M | 129.07M | 1.12M | 438.68M | 237.34M | 33M | 33M | 277M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | 283K | 519K | 3.96M | 1.22M | 4.67M | 12.34M | 0 | 8M | 2M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -17.04M | -30.57M | -46.74M | -75.39M | 108.11M | -282.25M | 432M | -330M | -176M |
| FCF Margin % | - | -21.64% | -5.6% | -5.03% | 1.39% | -0.74% | 3.86% | -2.82% | -0.68% |
| FCF Growth % | - | -0.79% | -0.53% | -0.61% | 2.43% | -3.61% | 2.53% | -1.76% | 0.47% |
| FCF per Share | -0.69 | -1.25 | -1.35 | -1.72 | 1.97 | -3.82 | 6.00 | -4.46 | -1.95 |
| FCF Conversion (FCF/Net Income) | 0.72x | 0.47x | 0.87x | 0.87x | -0.90x | -4.83x | -1.64x | 1.00x | 0.60x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -18.07% | -41.91% | -25.51% | -42.48% | -36.93% | 7.89% | -35.64% | -54.87% | -59.77% |
| Return on Invested Capital (ROIC) | - | -89.32% | -37.52% | -49.32% | -41.07% | 6.97% | -30.29% | -55.62% | -66.8% |
| Gross Margin | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | - | -3756.69% | -593.73% | -564.73% | -157.69% | 13.84% | -238.39% | -262.39% | -109.69% |
| Debt / Equity | - | - | - | - | 0.04x | 0.14x | 0.18x | 0.02x | 0.12x |
| Interest Coverage | - | - | - | - | - | - | -140.00x | -170.00x | -82.50x |
| FCF Conversion | 0.72x | 0.47x | 0.87x | 0.87x | -0.90x | -4.83x | -1.64x | 1.00x | 0.60x |
| Revenue Growth | - | - | 491.15% | 79.58% | 420% | 391.03% | -70.76% | 4.46% | 120.51% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Other Collaboration Revenue | - | - | 33M | 37M | 36M |
| Other Collaboration Revenue Growth | - | - | - | 12.12% | -2.70% |
| License and Development Services Revenue | - | - | 74M | - | - |
| License and Development Services Revenue Growth | - | - | - | - | - |
| Gilead License to Domvanalimab | - | 328.84M | - | - | - |
| Gilead License to Domvanalimab Growth | - | - | - | - | - |
| Gilead Access Rights | 15.42M | 30.91M | - | - | - |
| Gilead Access Rights Growth | - | 100.43% | - | - | - |
| Taiho License to Domvanalimab | - | 15M | - | - | - |
| Taiho License to Domvanalimab Growth | - | - | - | - | - |
| Taiho Access Rights | - | 7M | - | - | - |
| Taiho Access Rights Growth | - | - | - | - | - |
| Development Services for all Gilead Programs | - | 1.14M | - | - | - |
| Development Services for all Gilead Programs Growth | - | - | - | - | - |
| Gilead License To Zimberelimab | 55.1M | - | - | - | - |
| Gilead License To Zimberelimab Growth | - | - | - | - | - |
| Taiho Collaboration Agreement | 7M | - | - | - | - |
| Taiho Collaboration Agreement Growth | - | - | - | - | - |
Arcus Biosciences, Inc. (RCUS) reported $240.0M in revenue for fiscal year 2024.
Arcus Biosciences, Inc. (RCUS) grew revenue by 120.5% over the past year. This is strong growth.
Arcus Biosciences, Inc. (RCUS) reported a net loss of $349.0M for fiscal year 2024.
Arcus Biosciences, Inc. (RCUS) has a return on equity (ROE) of -59.8%. Negative ROE indicates the company is unprofitable.
Arcus Biosciences, Inc. (RCUS) had negative free cash flow of $464.0M in fiscal year 2024, likely due to heavy capital investments.